Table 5.
Demographic and clinical features of the patients with PD, atypical parkinsonian disorders (APDs) patients, and the controls.
| Feature | PD (n = 10), Mean ± SD | Controls (n = 10), Mean ± SD | APDs (n = 8), Mean ± SD |
|---|---|---|---|
| Male/female (N) | 4/6 | 7/3 | 3/5 |
| Age (years) | 60 ± 52 | 52 ± 13 | 63 ± 12 |
| Disease duration (years) | 7 ± 5 | - | 7 ± 7.5 |
| LEDD | 804 ± 514 | - | 641 ± 446 |
| HY | 2 ± 1 | - | |
| UPDRS III | 19 ± 12 | - | |
| Dementia | 0 | 0 | 1 |
| Depression | 0 | 0 | 3 |
| BMI | 27 ± 5 | 24 ± 3 | 26 ± 4 |
| Other drugs | Levothyroxine, aspirin, quetiapine, and angiotensin-converting enzyme inhibitor | Levothyroxine, beta-blockers, statins, and angiotensin-converting enzyme inhibitor | Quetiapine, sertraline, beta- blockers, statins, angiotensin- converting enzyme inhibitor, and tiapride |
LEDD—L-dopa equivalent daily dose; HY—modified Hoehn and Yahr rating scale; UPDRS III—Unified Parkinson’s Disease Rating Scale Part III.